Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
ChromaDex Corporation is a biotechnology business based in the US. ChromaDex Corporation shares (CDXC) are listed on the NASDAQ and all prices are listed in US Dollars. ChromaDex Corporation employs 110 staff and has a trailing 12-month revenue of around USD$56.9 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$2.5 - USD$9.99 |
---|---|
50-day moving average | USD$5.3991 |
200-day moving average | USD$4.9581 |
Wall St. target price | USD$7.9 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.595 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$56.9 million |
---|---|
Gross profit TTM | USD$25.8 million |
Return on assets TTM | -35.12% |
Return on equity TTM | -97.28% |
Profit margin | -39.86% |
Book value | $0.315 |
Market capitalisation | USD$589.5 million |
TTM: trailing 12 months
There are currently 2.4 million ChromaDex Corporation shares held short by investors – that's known as ChromaDex Corporation's "short interest". This figure is 4.5% down from 2.5 million last month.
There are a few different ways that this level of interest in shorting ChromaDex Corporation shares can be evaluated.
ChromaDex Corporation's "short interest ratio" (SIR) is the quantity of ChromaDex Corporation shares currently shorted divided by the average quantity of ChromaDex Corporation shares traded daily (recently around 289152.46098439). ChromaDex Corporation's SIR currently stands at 8.33. In other words for every 100,000 ChromaDex Corporation shares traded daily on the market, roughly 8330 shares are currently held short.
However ChromaDex Corporation's short interest can also be evaluated against the total number of ChromaDex Corporation shares, or, against the total number of tradable ChromaDex Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ChromaDex Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 ChromaDex Corporation shares in existence, roughly 40 shares are currently held short) or 0.0468% of the tradable shares (for every 100,000 tradable ChromaDex Corporation shares, roughly 47 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ChromaDex Corporation.
Find out more about how you can short ChromaDex Corporation stock.
We're not expecting ChromaDex Corporation to pay a dividend over the next 12 months.
ChromaDex Corporation's shares were split on a 1:3 basis on 13 April 2016. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ChromaDex Corporation shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for ChromaDex Corporation shares which in turn could have impacted ChromaDex Corporation's share price.
Over the last 12 months, ChromaDex Corporation's shares have ranged in value from as little as $2.5 up to $9.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChromaDex Corporation's is 1.5768. This would suggest that ChromaDex Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is headquartered in Los Angeles, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.